Manufacturing

Proprietary antibody technology

Two colleagues in blue shirts reviewing information on a laptop in a laboratory

We took a different approach.

SAB-142 is built on a proprietary platform that uses advanced genetic engineering and antibody science to generate targeted, fully human, multispecific antibodies without relying on human donors or convalescent plasma.

Our wholly owned, in-house platform has the potential to generate novel therapeutic candidates to address unmet needs in a wide range of human diseases.

Upstream: SAB BIO’s biosecure facility

Engineered biology

Our transchromosomic (Tc) bovines are genetically designed to produce fully human antibodies.

Targeted immunization

We immunized Tc bovines to naturally produce targeted antibodies.

Human antibody production

The engineered platform produces fully human, multispecific antibodies that circulate in the bloodstream.

Plasma collection

Tc Bovines are plasma donors, and antibodies are collected in the form of plasma.

Downstream: SAB BIO’s cGMP facility

Purified

Antibodies are isolated from the pooled plasma.

Formulated

The purified antibodies are used to generate a fully human, multispecific antibody therapy.

Why it matters

Doctor talking with a young patient and his caregiver in an exam room

Our platform generates fully human antibodies, reducing the potential for immune reactions associated with non-human sources.

Supply is consistent and scalable because 
no human donors are required.

There are high barriers to entry because this unique platform leverages a multilevel intellectual property (IP) strategy with no biosimilar pathway.

See our pipeline